Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck bravecto — Full-year sales ($B, as reported in Form 10-K)
Form 10-K Animal Health MD&A
Latest, FY2025
1.10
Period ended Dec 31, 2025
Change on a year earlier
0.0%
1.10 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Full-year sales ($B, as reported in Form 10-K) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.10 | 0.0% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1.10 | 0.0% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 1.10 | +10.0% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1.00 | – | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Full-year sales ($B, as reported in Form 10-K), annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_bravecto_fy_b
See every metric in the Merck KPI table. Data updated Oct 26, 2026.